1 |
Al-Tawfiq, J. A., Zumla, A., Gautret, P., Gray, G. C., Hui, D.S., Al-Rabeeah, A. A. and Memish, Z. A. : Surveillance for emerging respiratory viruses. Lancet Infect. Dis. 14, 992 (2014).
DOI
|
2 |
Assiri, A., McGeer, A., Perl, T. M., Price, C. S., Al Rabeeah, A. A., Cummings, D. A., Alabdullatif, Z. N., Assad, M., Almulhim, A., Makhdoom, H., Madani, H., Alhakeem, R., Al-Tawfiq, J. A., Cotton, M., Watson, S. J., Kellam, P., Zumla, A. I. and Memish, Z. A. : KSA MERS-CoV Investigation Team.: Hospital outbreak of Middle East respiratory syndrome coronavirus. N. Engl. J. Med. 369, 407 (2013).
DOI
|
3 |
Assiri, A., Al-Tawfiq, J. A., Al-Rabeeah, A. A., Al-Rabiah, F. A., Al-Hajjar, S., Al-Barrak, A., Flemban, H., Al-Nassir, W. N., Balkhy, H. H., Al-Hakeem, R. F., Makhdoom, H. Q., Zumla, A. I. and Memish, Z. A. : Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Lancet Infect. Dis. 13, 752 (2013).
DOI
|
4 |
Memish, Z. A., Al-Tawfiq, J. A., Assiri, A., AlRabiah, F. A., Al Hajjar, S., Albarrak, A., Flemban, H., Alhakeem, R. F., Makhdoom, H. Q., Alsubaie, S. and Al-Rabeeah, A. A. : Middle East respiratory syndrome coronavirus disease in children. Pediatr. Infect. Dis. J. 33, 904 (2014).
DOI
|
5 |
Zumla, A., Memish, Z. A., Maeurer, M., Bates, M., Mwaba, P., Al-Tawfiq, J. A., Denning, D. W., Hayden, F. G. and Hui, D. S. : Emerging novel and antimicrobial-resistant respiratory tract infections: new drug development and therapeutic options. Lancet Infect. Dis. 14, 1136 (2014).
DOI
|
6 |
Khalid, M., Al Rabiah, F., Khan, B., Al Mobeireek, A., Butt, T. S. and Al Mutairy, E. : Ribavirin and interferon- as primary and preventive treatment for Middle East respiratory syndrome coronavirus: a preliminary report of two cases. Antivir. Ther. 20, 87 (2015).
|
7 |
Khalid, M., Khan, B., Al Rabiah, F., Alismaili, R., Saleemi, S., Rehan-Khaliq, A. M., Weheba, I., Al Abdely, H., Halim, M., Nadri, Q. J., Al Dalaan, A. M., Zeitouni, M., Butt, T, and Al Mutairy, E. : Middle Eastern Respiratory Syndrome Corona Virus (MERS CoV): case reports from a tertiary care hospital in Saudi Arabia. Ann. Saudi. Med. 34, 396 (2014).
DOI
|
8 |
European Centre for Disease Prevention and Control. Epidemiological update: Middle East respiratory syndrome coronavirus (MERS-CoV) Available at http://ecdc.europa.eu/en/press/news/Pages/News.aspx (accessed on September 2, 2015).
|
9 |
Korea Centers for Disease Control and Prevention. Middle East respiratory syndrome information. Available at http://www.mers.go.kr/mers/html/jsp/main.jsp (accessed on September 2, 2015).
|
10 |
최재욱, 김경희, 조용민, 김상후 : 한국 메르스 감염의 역학현황과 공중보건학적 대응조치 방향. 대한의사협회지 58, 487 (2015).
|
11 |
de Wilde, A. H., Jochmans, D., Posthuma, C. C., Zevenhoven-Dobbe, J. C., van Nieuwkoop, S., Bestebroer, T. M., van den Hoogen, B. G., Neyts, J. and Snijder, E. J. : Screening of an FDA-approved compound library identifies four smallmolecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrob. Agents Chemother. 58, 4875 (2014).
DOI
|
12 |
Falzarano, D., de Wit, E., Martellaro, C., Callison, J., Munster, V. J. and Feldmann, H. : Inhibition of novel coronavirus replication by a combination of interferon-and ribavirin. Sci. Rep. 3, 1686 (2013).
DOI
|
13 |
Shalhoub, S., Farahat, F., Al-Jiffri, A., Simhairi, R., Shamma, O., Siddiqi, N. and Mushtaq, A. : IFN- or IFN- in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective study. J. Antimicrob. Chemother. 70, 2129 (2015).
DOI
|
14 |
Zumla, A., Hui, D. S. and Perlman, S. : Middle East respiratory syndrome. Lancet. doi:10.1016/S0140-6736(15)60454-8 (2015).
DOI
|
15 |
Coleman, C. M. and Frieman, M. B. : Treating MERS-CoV during an outbreak. Lancet Infect. Dis. 14, 1030 (2014).
DOI
|
16 |
Momattin, H., Mohammed, K., Zumla, A., Memish, Z. A. and Al-Tawfiq, J. A. : Therapeutic options for Middle East respiratory syndrome coronavirus (MERS-CoV)--possible lessons from a systematic review of SARS-CoV therapy. Int. J. Infect. Dis. 17, e792 (2013).
DOI
|
17 |
대한감염학회/대한화학요법학회: MERS 항바이러스제 치료지침, version 1.1. Available at http://www.ksid.or.kr/mail/file/ MERS02.pdf (accessed on July 27, 2015).
|
18 |
U.S. Preventive Services Task Force: Guide to clinical preventive services: report of the U.S. Preventive Services Task Force 1st ed., DIANE Publ. Co., Pennsylvania, p. 263 (1989).
|
19 |
Omrani, A. S., Saad, M. M., Baig, K., Bahloul, A., Abdul-Matin, M., Alaidaroos, A. Y., Almakhlafi, G. A., Albarrak, M. M., Memish, Z. A. and Albarrak, A. M. : Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study. Lancet Infect. Dis. 14, 1090 (2014).
DOI
|
20 |
Al-Tawfiq, J. A., Momattin, H., Dib, J. and Memish, Z. A. : Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study. Int. J. Infect. Dis. 20, 42 (2014).
DOI
|
21 |
de Wilde, A. H., Raj, V. S., Oudshoorn, D., Bestebroer, T. M., van Nieuwkoop, S., Limpens, R. W., Posthuma, C. C., van der Meer, Y., Barcena, M. and Haagmans, B. L., Snijder, E. J. and van den Hoogen, B. G. : MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-? treatment. J. Gen. Virol. 94, 1749 (2013).
DOI
|
22 |
Falzarano, D., de Wit, E., Rasmussen, A. L., Feldmann, F., Okumura, A., Scott, D. P., Brining, D., Bushmaker, T., Martellaro, C., Baseler, L., Benecke, A. G., Katze, M. G., Munster, V. J. and Feldmann, H. : Treatment with interferon- and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. Nat. Med. 19, 1313 (2013).
DOI
|
23 |
Stockman, L. J., Bellamy, R. and Garner, P. : SARS: systematic review of treatment effects. PLoS Med. 3, e343 (2006).
DOI
|
24 |
Centers for Disease Control and Prevention. Severe Acute Respiratory Syndrome (SARS). Available at http://www.cdc.gov/sars/ (accessed on July 27, 2015).
|
25 |
Hart, B. J., Dyall, J., Postnikova, E., Zhou, H., Kindrachuk, J., Johnson, R. F., Olinger, G. G. Jr., Frieman, M. B., Holbrook, M. R., Jahrling, P. B. and Hensley, L. : Interferon- and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays. J. Gen. Virol. 95, 571 (2015).
|
26 |
Chan, J. F., Yao, Y., Yeung, M. L., Deng, W., Bao, L., Jia, L., Li, F., Xiao, C., Gao, H., Yu, P., Cai, J. P., Chu, H., Zhou, J., Chen, H., Qin, C. and Yuen, K. Y. : Treatment with lopinavir/ritonavir or interferon-improves outcome of MERS-CoV infection in a non-human primate model of common marmoset. J. Infect. Dis. in press (2015).
|
27 |
To, K. K., Hung, I. F., Chan, J. F. and Yuen, K. Y. : From SARS coronavirus to novel animal and human coronaviruses. J. Thorac. Dis. 5, S103 (2013).
|